Multiple Eruptive Dermatofibromas in a Patient Receiving Efalizumab

A Case of Idiopathic Dermatofibromatosis

“…İyatrojenik immünsupresyon vakalarında da MED gelişimi bildirilmiştir. [22][23][24][25][26][27][28] Tablo 1'de literatürde 18 yaş ve altında bildirilen multipl dermatofibrom olguları görül-mektedir. 4,6,[29][30][31] Literatür taranarak elde edilen 18 yaş altı MED tanılı olgular incelendiğinde cinsiyet açısın-dan fark saptanmamış olup, olguların hiçbirinde eşlik eden hastalık veya sistemik tedavi kullanımı bildirilmemiştir.…”

Multiple Clustered Dermatofibromas Following Ustekinumab Treatment for Psoriasis Vulgaris

“…7 In the present case, with regards to the role of ustekinumab, causation cannot be proven; however, a similar case has been described with the biological drug efalizumab. 8 Moreover, the development of multiple eruptive dermatofibromas in immunomodulated situations could be explained by the inhibition of downregulatory T cells. [8][9][10] Systemic lupus erythematosus is the most common underlying disease associated with multiple eruptive dermatofibromas.…”

“…8 Moreover, the development of multiple eruptive dermatofibromas in immunomodulated situations could be explained by the inhibition of downregulatory T cells. [8][9][10] Systemic lupus erythematosus is the most common underlying disease associated with multiple eruptive dermatofibromas. 9 However, it is important to note that the degree of immunosuppression does not seem to correlate with the number of dermatofibromas.…”

Rapid Onset and Fatal Outcome of Two Squamous Cell Carcinomas of the Genitalia in a Patient Treated with Etanercept for Cutaneous Psoriasis

“…Owing to the pharmacological profile of these molecules, other clinical features might be more frequent in anti-TNF-␣ -associated cutaneous SCC such as multiple tumors, rapid local growth and perhaps a higher metastatic potential, all characteristics featured by our patient. On the other hand, it is of interest to note that the use of efalizumab, another non-anti-TNF-␣ biological agent currently used in psoriasis, has not been linked to a significant increase in the patients' risk of developing skin malignancies [7] although the occurrence of multiple dermatofibromas, a cutaneous condition sometimes also related to immunodeficiency, has recently been reported in this therapeutic setting [8] . Although definitive conclusions cannot be drawn on so few cases, a very careful examination of the whole body surface including the genitals must be carried out on a regular basis in psoriasis patients receiving anti-TNF-␣ agents.…”